Donald Max Engelman | |
---|---|
Alma mater | |
Awards | |
Website | medicine |
Born | 1941 (age 82–83) |
Education | Reed College, Yale University |
Awards | Guggenheim fellow |
Scientific career | |
Fields | Cancer drugs and treatments |
Institutions | Yale University |
Thesis | Solubilization and Aggregation Properties of Membrane Components from Mycoplasma laidlawii (1968) |
Doctoral students | Mark A. Lemmon[1][2] |
Donald Max Engelman (born 1941) is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences,[3] a fellow of the National Institutes of Health, and has been a Guggenheim fellow.[4] He served as the editor of the Annual Review of Biophysics and Biophysical Chemistry (1984–1993).[5]
He is a director of the Stryker Corporation.[6] He is involved in the creation of new cancer drugs and treatments.[7] For example, Engelman is involved in research to use peptides to aid in destroying tumors.[8]